ELTP ELITE PHARMACEUTICALS INC COM NEW revenue, earnings and financials
For the quarter ended June 30, 2026, ELITE PHARMACEUTICALS INC COM NEW reported revenue of $32.4M (down 19.5% from a year earlier), net income of $5.91M and diluted EPS of $0.01; over the last four quarters revenue was $141M and net income $56.7M; for the fiscal year ended March 2026 revenue was $149M, up 77.1% on the year before.
ELTP annual revenue and earnings
- Fiscal year ended Mar 2026: revenue $149M, gross profit $75.0M, operating income $49.1M, net income $44.9M (margin 30.1%), EPS $0.03
- Fiscal year ended Mar 2025: revenue $84.0M, gross profit $40.1M, operating income $19.6M, net income −$4.31M (margin -5.1%), EPS $0.00
- Fiscal year ended Mar 2024: revenue $56.6M, gross profit $26.4M, operating income $10.8M, net income $20.1M (margin 35.5%), EPS $0.02
- Fiscal year ended Mar 2023: revenue $34.2M, gross profit $16.6M, operating income $3.68M, net income $3.56M (margin 10.4%), EPS $0.00
- Fiscal year ended Mar 2022: revenue $32.3M, gross profit $14.8M, operating income $5.07M, net income $8.90M (margin 27.6%), EPS $0.01
ELTP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $32.4M (down 19.5% year over year), net income $5.91M, EPS $0.01
- Quarter ended Mar 31, 2026 (from the annual report): revenue $40.7M (up 27.4% year over year), net income $18.5M, EPS $0.02
- Quarter ended Dec 31, 2025: revenue $31.6M (up 119.9% year over year), net income $18.6M, EPS $0.01
- Quarter ended Sep 30, 2025: revenue $36.3M (up 92.4% year over year), net income $13.7M, EPS $0.01
- Quarter ended Jun 30, 2025: revenue $40.2M (up 113.9% year over year), net income −$5.88M, EPS −$0.01
- Quarter ended Mar 31, 2025 (from the annual report): revenue $32.0M (up 78.3% year over year), net income $17.0M, EPS $0.02
- Quarter ended Dec 31, 2024: revenue $14.4M (down 7.6% year over year), net income −$10.9M, EPS −$0.01
- Quarter ended Sep 30, 2024: revenue $18.9M (up 33.4% year over year), net income −$11.0M, EPS −$0.01
- Quarter ended Jun 30, 2024: revenue $18.8M (up 109.4% year over year), net income $616K, EPS $0.00
- Quarter ended Mar 31, 2024 (from the annual report): revenue $17.9M (up 107.6% year over year), net income $3.33M, EPS $0.01
- Quarter ended Dec 31, 2023: revenue $15.5M (up 68.0% year over year), net income $706K, EPS $0.00
- Quarter ended Sep 30, 2023: revenue $14.2M (up 64.9% year over year), net income $14.9M, EPS $0.01
- Quarter ended Jun 30, 2023: revenue $8.98M (up 17.0% year over year), net income $1.14M, EPS $0.00
- Quarter ended Mar 31, 2023 (from the annual report): revenue $8.65M (up 12.7% year over year), net income −$1.23M, EPS $0.00
- Quarter ended Dec 31, 2022: revenue $9.25M (up 3.1% year over year), net income $2.97M, EPS $0.00
- Quarter ended Sep 30, 2022: revenue $8.59M (up 0.3% year over year), net income $1.52M, EPS $0.00
- Quarter ended Jun 30, 2022: revenue $7.67M (up 8.7% year over year), net income $306K, EPS $0.00
- Quarter ended Mar 31, 2022 (from the annual report): revenue $7.67M, net income $2.43M, EPS $0.01
- Quarter ended Dec 31, 2021: revenue $8.97M, net income $2.28M, EPS $0.00
- Quarter ended Sep 30, 2021: revenue $8.56M, net income $1.80M, EPS $0.00
ELTP cash flow, buybacks and dividends
- Fiscal year ended Mar 2026: operating cash flow $23.7M, share buybacks n/a
- Fiscal year ended Mar 2025: operating cash flow $7.46M, share buybacks n/a
- Fiscal year ended Mar 2024: operating cash flow −$3.24M, share buybacks n/a
- Fiscal year ended Mar 2023: operating cash flow $3.34M, share buybacks n/a
- Fiscal year ended Mar 2022: operating cash flow $6.51M, share buybacks n/a
ELTP balance sheet
- Jun 30, 2026: cash n/a, total assets $140M, total liabilities $34.8M, shareholders' equity $105M
- Mar 31, 2026: cash n/a, total assets $138M, total liabilities $39.4M, shareholders' equity $98.9M
- Dec 31, 2025: cash n/a, total assets $126M, total liabilities $46.1M, shareholders' equity $80.3M
- Sep 30, 2025: cash n/a, total assets $117M, total liabilities $55.7M, shareholders' equity $61.6M
- Jun 30, 2025: cash n/a, total assets $111M, total liabilities $63.7M, shareholders' equity $47.7M
- Mar 31, 2025: cash n/a, total assets $96.4M, total liabilities $42.9M, shareholders' equity $53.5M
- Dec 31, 2024: cash n/a, total assets $90.8M, total liabilities $54.3M, shareholders' equity $36.4M
- Sep 30, 2024: cash n/a, total assets $88.2M, total liabilities $40.9M, shareholders' equity $47.3M
What is ELTP's revenue?
ELITE PHARMACEUTICALS INC COM NEW reported $141M of revenue over its last four quarters, through June 30, 2026.
Is ELTP profitable?
Yes. ELITE PHARMACEUTICALS INC COM NEW earned $56.7M over the last four quarters.
What is ELTP's EPS?
Diluted earnings per share over the last four quarters were $0.05; $0.01 in the latest quarter.